Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Jolyon, Jesty"'
Autor:
Gaurav Girdhar, Michalis Xenos, Yared Alemu, Wei-Che Chiu, Bryan E Lynch, Jolyon Jesty, Shmuel Einav, Marvin J Slepian, Danny Bluestein
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e32463 (2012)
Mechanical circulatory support (MCS) devices provide both short and long term hemodynamic support for advanced heart failure patients. Unfortunately these devices remain plagued by thromboembolic complications associated with chronic platelet activat
Externí odkaz:
https://doaj.org/article/d372756baacc4eddb4f91283bce940a5
Autor:
Jolyon Jesty, Marcus Hutchinson, Jawaad Sheriff, Phat L. Tran, Danny Bluestein, Tracy DeCook, Marvin J. Slepian
Publikováno v:
Artificial Organs. 40:586-595
Implantation of mechanical circulatory support (MCS) devices-ventricular assist devices and the total artificial heart-has emerged as a vital therapy for advanced and end-stage heart failure. Unfortunately, MCS patients face the requirement of life-l
Autor:
Jolyon Jesty, Danny Bluestein, Gaurav Girdhar, Wei Che Chiu, Marvin J. Slepian, Jawaad Sheriff
Publikováno v:
Journal of Thrombosis and Thrombolysis. 37:499-506
Ventricular assist devices (VADs) are implanted in patients with end-stage heart failure to provide both short- and long-term hemodynamic support. Unfortunately, bleeding and thromboembolic complications due to the severely disturbed, dynamic flow co
Autor:
Jawaad, Sheriff, João Silva, Soares, Michalis, Xenos, Jolyon, Jesty, Marvin J, Slepian, Danny, Bluestein
Publikováno v:
Annals of Biomedical Engineering. 41:1279-1296
The advent of implantable blood-recirculating devices such as left ventricular assist devices and prosthetic heart valves provides a viable therapy for patients with end-stage heart failure and valvular disease. However, device-generated pathological
Autor:
Marvin J. Slepian, Marcus Hutchinson, Jolyon Jesty, Tracy DeCook, Danny Bluestein, Jawaad Sheriff, Phat L. Tran
Publikováno v:
EMBC
Mechanical circulatory support (MCS) devices, such as ventricular assist devices and the total artificial heart, have emerged as a vital therapy for advanced and end-stage heart failure. However, MCS patients face life-long antiplatelet and anticoagu
Autor:
Richard T. Schoephoerster, Thomas E. Claiborne, Jolyon Jesty, Siobhain Gallocher-Lowe, Leonard Pinchuk, Danny Bluestein, Jawaad Sheriff, Yasushi P. Kato, Gaurav Girdhar
Publikováno v:
ASAIO Journal. 57:26-31
Trileaflet polymeric prosthetic aortic valves (AVs) produce hemodynamic characteristics akin to the natural AV and may be most suitable for applications such as transcatheter implantation and mechanical circulatory support (MCS) devices. Their succes
Autor:
Yared Alemu, Shmuel Einav, Danny Bluestein, Jolyon Jesty, Michalis Xenos, Marvin J. Slepian, Gaurav Girdhar
Publikováno v:
Journal of Biomechanics. 43:2400-2409
Patients who receive prosthetic heart valve (PHV) implants require mandatory anticoagulation medication after implantation due to the thrombogenic potential of the valve. Optimization of PHV designs may facilitate reduction of flow-induced thrombogen
Publikováno v:
Nicotine & Tobacco Research. 10:1737-1744
Nicotine is a primary constituent of tobacco and smoke, and its roles in causing addiction and causing disease are commonly conflated. In the present work, we investigated whether nicotine protects smokers' platelets against smoke-induced activation
Publikováno v:
Blood Coagulation & Fibrinolysis. 17:593-597
A woman with gross hematuria was shown to have a severe isolated factor V deficiency due to a factor V inhibitor of 200 U/ml titer. Hematuria persisted despite multiple infusions of plasma but, after one transfusion with 1 U platelets, urine red bloo
Autor:
Jolyon Jesty, Danny Bluestein, Siobhain Lynn Gallocher, Wei Yin, Leonard Pinchuk, Richard T. Schoephoerster
Publikováno v:
Artificial Organs. 29:826-831
Polymer heart valves have been under investigation since the 1960s, but their success has been hampered by an overall lack of durability mainly due to calcification of the leaflets and a relatively high rate of thromboembolic complications. A new pol